RT Journal Article
SR Electronic
T1 The role of the change of tumor metabolic volume (MV) for monitoring cancer therapy in 18F-FDG-PET/CT
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 371P
OP 371P
VO 49
IS supplement 1
A1 Nagamachi, Shigeki
A1 Kiyohara, Shogo
A1 Wakamatsu, Hideyuki
A1 Fujita, Seigo
A1 Futami, Shigemi
A1 Tamura, Shozo
A1 Arita, Hideo
YR 2008
UL http://jnm.snmjournals.org/content/49/supplement_1/371P.3.abstract
AB 1568 Objectives: We performed the current study to investigate the usefulness of MV in monitoring therapeutic effects in various cancers. Methods: We evaluated the serial change of maximum SUV (SUVmax) and metabolic volume (MV) obtained by 18F-FDG-PET/CT performed in forty-five patients with various cancer. The patients include 14 lung cancers, 12 malignant lymphomas, 7 colon cancer, 5 esophageal cancers and 7 other cancers. The value of MV was calculated in condition at 50% cutoffs. Both SUVmax and MV were obtained before and after cancer therapy. We evaluated the correlation between SUVmax and MV. We also evaluated the correlation of % change of both indices, calculated as (index obtained at post-therapy / index obtained at pre-therapy). Results: The value of SUVmax weakly correlated positively with that of MV (r=0.52). In contrast, the correlation between %change of both index was fairly good (r=0.73). Conclusions: The serial change of tumor metabolic volume correlates with that of SUVmax. The tumor metabolic volume obtained by 18F-FDG-PET/CT , %change in particular, is useful index for monitoring the therapeutic effects in cancer therapy.